What we did this month.

We started this log because the work between investor updates is what compounds. Patents filed, advisors signed, code shipped, cohort sessions captured, regulatory milestones closed. Most of it does not earn a press release. Some of it does. All of it is real, and we wanted a place to write it down month by month in the company's own voice with nothing dressed up.

Updates go up on the first business day of each month with the prior month's substantive items. The format is plain on purpose: a date, a thing that happened, what it changes. No marketing copy. No forward looking statements beyond labeled near term milestones.

May 2026

Intellectual property

Filed our sixth U.S. provisional patent application on May 7, 2026: a forward looking compute architecture for fusing involuntary signals across modalities at scale. On May 27, 2026 we filed three more, extending the platform to neurodegenerative disease and dementia risk, oncologic detection from ocular and retinal signs, and infectious disease detection. This brings the active provisional portfolio to nine, all filed between January 2026 and May 2026, covering the d-CIIV scoring engine, the fused impact telemetry architecture, the optical and retinal modalities, stroke detection and time of onset estimation, psychiatric severity and treatment response, the compute layer, neurodegeneration and dementia risk, oncologic detection, and infectious disease. Provisional filings are not granted patents; non provisional conversions follow on statutory deadlines.

Team

Maya I. Rubio joined as co-founder, leading research strategy across active field cohorts and FDA regulatory engagement. Maya's mandate covers pre-submission Q-Sub design, pivotal validation cohort architecture, and 510(k) preparation. The founding team is now three: Justin B. Bordner (Founder), William M. Teppig Jr. (Co-Founder), Maya I. Rubio (Co-Founder). Operations support: Matthew R. Barraco (Medicine and Clinical), Shaun P. Padden (Revenue and Operations), Bryce M. Walker (Athlete and Organization Relations), Kariq D. Waters (Social Media). Clinical and scientific advisory board in active recruitment.

Field data collection

Active baseline captures continued in two field cohorts: a U.S. Mixed Martial Arts cohort of active roster fighters captured between competition windows, and a Ukraine civilian and soldier cohort with blast and impact exposure. Volume remains small. Pivotal cohort enrollment is the powered validation event and begins in the fourth quarter of 2026. Reports about our cohort data presented before then are observational, not powered, and labeled accordingly.

Regulatory engagement

Initial outreach completed for pre-submission Q-Sub engagement with FDA Center for Devices and Radiological Health targeting the concussion likelihood and TBI severity indications. Target Q-Sub submission: third quarter 2026.

Early policy outreach: introductory conversations have begun with federal offices interested in the unmet TBI screening need. These are exploratory only. No contracts, grants, partnerships, or endorsements have followed. No government agency or member of Congress has endorsed Chronic Trace or committed to procure it.

Platform engineering

Capture pipeline migration in flight from a third party in browser computer vision model to first party operating system native vision APIs on the platform's primary deployment hardware. The migration substantially improves signal precision on the channels that matter clinically (smooth pursuit, saccadic latency, postural sway, pupillary reflex on infrared equipped devices) and materially strengthens the analytical validation argument for the eventual 510(k) submission by replacing a third party model dependency with a first party API on a defined device matrix.

Two additional scored tests scaffolded this sprint, with integration into the capture battery in progress: a Simple Reaction Time test with deliberate slowing detection on the distribution shape, and an Anti-Saccade prefrontal inhibition probe that measures the published prefrontal cortex biomarker most associated with concussion (pro-saccade error rate). Both tests follow the same server side scoring pattern as the existing battery (math protected, types and client wrapper public).

Documents and assets

Crowdfunding whitepaper, investor one pager, FAQ and risk disclosures, and a 14 slide crowdfunding pitch deck were completed and published as internal review artifacts. Pre launch reservation posture, no money solicited or accepted. Public facing copy refresh on chronictrace.com to reflect the current four live tests, with two more in integration. Long form essays published in the research section: the gaming resistance comparison, the parent guide, the founder's story, and the regulatory posture explainer.

Capital

Pre launch testing the waters reservation page active at chronictrace.com/invest. Regulation Crowdfunding offering planned through a registered funding portal. Offering is not yet open. Reservation page collects non binding indications of interest only. Per applicable rules, no money is being solicited or accepted; no offer to buy securities can be accepted and no part of any purchase price can be received until an offering statement is filed with and qualified by the relevant regulator.

Format for future entries

Each month's entry will use the same subsection structure so readers can find what they care about quickly. The seven running headings are intellectual property, team, field data collection, regulatory engagement, platform engineering, documents and assets, and capital. If a heading has nothing substantive that month, we will say so rather than fill it with motion.

Specific numbers we will publish on this log when they become available: cumulative baseline captures by cohort, advisor signings (with permission), Q-Sub feedback summary (high level, not the verbatim FDA response, which is not public), pivotal enrollment progress against the protocol target, media coverage of substance, and any third party validation events.

Numbers we will not publish on this log: clinical sensitivity and specificity against reference instruments before the pivotal cohort closes; revenue or commercial terms; investor or partner identities without their consent.

Next update: June 1, 2026.